Sara Ashtari1, Mohamad Amin Pourhoseingholi1, Mohamad Reza Zali1. 1. Sara Ashtari, Mohamad Amin Pourhoseingholi, Mohamad Reza Zali, Gastroenterology and Liver Disease Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Science, Tehran 1985717413, Iran.
Abstract
AIM: To review all of epidemiological aspects of non-alcoholic fatty liver disease (NAFLD) and also prevent this disease is examined. METHODS: We conducted a systematic review according to the PRISMA guidelines. All searches for writing this review is based on the papers was found in PubMed (MEDLINE), Cochrane database and Scopus in August and September 2014 for topic of NAFLD in Asia and the way of prevention of this disease, with no language limitations. All relevant articles were accessed in full text and all relevant materials was evaluated and reviewed. RESULTS: NAFLD is the most common liver disorder in worldwide, with an estimated with 20%-30% prevalence in Western countries and 2%-4% worldwide. The prevalence of NAFLD in Asia, depending on location (urban vs rural), gender, ethnicity, and age is variable between 15%-20%. According to the many studies in the world, the relationship between NAFLD, obesity, diabetes mellitus, and metabolic syndrome (MS) is quiet obvious. Prevalence of NAFLD in Asian countries seems to be lower than the Western countries but, it has increased recently due to the rise of obesity, type 2 diabetes and MS in this region. One of the main reasons for the increase in obesity, diabetes and MS in Asia is a lifestyle change and industrialization. Today, NAFLD is recognized as a major chronic liver disease in Asia. Therefore, prevention of this disease in Asian countries is very important and the best strategy for prevention and control of NAFLD is lifestyle modifications. Lifestyle modification programs are typically designed to change bad eating habits and increase physical activity that is associated with clinically significant improvements in obesity, type 2 diabetes and MS. CONCLUSION: Prevention of NAFLD is very important in Asian countries particularly in Arab countries because of high prevalence of obesity, diabetes and MS.
AIM: To review all of epidemiological aspects of non-alcoholic fatty liver disease (NAFLD) and also prevent this disease is examined. METHODS: We conducted a systematic review according to the PRISMA guidelines. All searches for writing this review is based on the papers was found in PubMed (MEDLINE), Cochrane database and Scopus in August and September 2014 for topic of NAFLD in Asia and the way of prevention of this disease, with no language limitations. All relevant articles were accessed in full text and all relevant materials was evaluated and reviewed. RESULTS: NAFLD is the most common liver disorder in worldwide, with an estimated with 20%-30% prevalence in Western countries and 2%-4% worldwide. The prevalence of NAFLD in Asia, depending on location (urban vs rural), gender, ethnicity, and age is variable between 15%-20%. According to the many studies in the world, the relationship between NAFLD, obesity, diabetes mellitus, and metabolic syndrome (MS) is quiet obvious. Prevalence of NAFLD in Asian countries seems to be lower than the Western countries but, it has increased recently due to the rise of obesity, type 2 diabetes and MS in this region. One of the main reasons for the increase in obesity, diabetes and MS in Asia is a lifestyle change and industrialization. Today, NAFLD is recognized as a major chronic liver disease in Asia. Therefore, prevention of this disease in Asian countries is very important and the best strategy for prevention and control of NAFLD is lifestyle modifications. Lifestyle modification programs are typically designed to change bad eating habits and increase physical activity that is associated with clinically significant improvements in obesity, type 2 diabetes and MS. CONCLUSION: Prevention of NAFLD is very important in Asian countries particularly in Arab countries because of high prevalence of obesity, diabetes and MS.
Authors: K Khunti; N Taub; D Webb; B Srinivasan; J Stockman; S J Griffin; R K Simmons; M J Davies Journal: Diabet Med Date: 2012-03 Impact factor: 4.359
Authors: Hellan Kang; Joel K Greenson; Jason T Omo; Cewin Chao; Debra Peterman; Lilian Anderson; Laura Foess-Wood; Mary A Sherbondy; Hari S Conjeevaram Journal: Am J Gastroenterol Date: 2006-10 Impact factor: 10.864
Authors: Erik Kirk; Dominic N Reeds; Brian N Finck; S Mitra Mayurranjan; Mitra S Mayurranjan; Bruce W Patterson; Samuel Klein Journal: Gastroenterology Date: 2009-01-25 Impact factor: 22.682
Authors: Manar N Amin; Muhammad A Rushdi; Raghda N Marzaban; Ayman Yosry; Kang Kim; Ahmed M Mahmoud Journal: Biomed Signal Process Control Date: 2019-04-05 Impact factor: 3.880
Authors: Rizwana Abdul Ghani; Muhammad Saqlain; Muhammad Mobeen Zafar; Shagufta Jabeen; Syed Muhammad Saqlan Naqvi; Ghazala Kaukab Raja Journal: Pak J Med Sci Date: 2017 Jan-Feb Impact factor: 1.088